We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top Stock Reports for Walgreens Boots, Duke Energy & Stryker
Read MoreHide Full Article
Wednesday, December 12, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walgreens Boots (WBA - Free Report) , Duke Energy (DUK - Free Report) and Stryker (SYK - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Walgreens Boots’ shares have outperformed the Zacks Drug Stores industry over the past three months, gaining +16.1% vs. +3.5%. The company's Retail Pharmacy USA division witnessed comparable prescription growth and benefited from a strong retail prescription market in the last reported quarter.
Meanwhile, low prescription volume and continuing government reimbursement pressure in the United Kingdom, have been leading to sluggishness in Retail Pharmacy International division. However, the Zacks analyst likes solid pharmacy sales growth which reflects synergies from Rite Aid store additions.
Walgreens Boots Alliance, with Express Scripts and Kroger, which aims to expand its existing group purchasing efforts and product offerings is a major positive. The launch of its next-day prescription delivery service with FedEx buoys optimism. Yet, the ongoing generic drug inflation is hurting Walgreens' pharmacy margins. Walgreens Boots faces tough competition along with currency fluctuations.
Shares of Buy-ranked Duke Energy have outperformed the Zacks Electric Power industry in the past year, gaining +3.7% vs +0.5%. Duke Energy invests heavily in infrastructure and expansion projects. It boasts a robust five-year capital plan and currently looks forward to invest about $48.2 billion in its overall growth projects in the 2018-2022 time frame.
The Zacks analyst thinks this investment plan will drive earnings base growth in the company’s combined electric and gas businesses of approximately 6% over the next five years. It is also looking to invest heavily in cleaner power, natural gas infrastructure and the energy grid during the next 10 years.
In particular, Duke Energy will invest $11 billion to generate cleaner energy through renewables and natural gas as it moves to a low-carbon future. However, Duke Energy faces challenges from severe weather conditions and natural calamities, which may result in breaking down and damaging its infrastructure.
Buy-ranked Stryker’s shares have gained +12% in the past year, outperforming the Zacks Medical Products industry, which has increased +1.4% over the same period. The Zacks analyst thinks that the company continues to gain from its Mako robotics platform, which has been the key driver of its core Orthopaedic segment.
In fact, the company witnessed solid growth in Mako robot installations in recent times. Surging domestic sales is another positive. Moreover, solid performance in emerging markets and Europe paints a bright picture. Solid expansion in operating margin is encouraging as well. Raised guidance for 2018 buoys optimism.
On the flip side, Stryker’s gross margin has been declining. Total debt on the balance sheet remains unchanged, adding to the company’s woes. The Trauma & Extremities business had moderate growth lately as it was affected by softness in the market and product supply issues. Stiff competition in the MedTech space is likely to mar Stryker’s prospects.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Stock Reports for Walgreens Boots, Duke Energy & Stryker
Wednesday, December 12, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walgreens Boots (WBA - Free Report) , Duke Energy (DUK - Free Report) and Stryker (SYK - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Walgreens Boots’ shares have outperformed the Zacks Drug Stores industry over the past three months, gaining +16.1% vs. +3.5%. The company's Retail Pharmacy USA division witnessed comparable prescription growth and benefited from a strong retail prescription market in the last reported quarter.
Meanwhile, low prescription volume and continuing government reimbursement pressure in the United Kingdom, have been leading to sluggishness in Retail Pharmacy International division. However, the Zacks analyst likes solid pharmacy sales growth which reflects synergies from Rite Aid store additions.
Walgreens Boots Alliance, with Express Scripts and Kroger, which aims to expand its existing group purchasing efforts and product offerings is a major positive. The launch of its next-day prescription delivery service with FedEx buoys optimism. Yet, the ongoing generic drug inflation is hurting Walgreens' pharmacy margins. Walgreens Boots faces tough competition along with currency fluctuations.
(You can read the full research report on Walgreens Boots here >>>).
Shares of Buy-ranked Duke Energy have outperformed the Zacks Electric Power industry in the past year, gaining +3.7% vs +0.5%. Duke Energy invests heavily in infrastructure and expansion projects. It boasts a robust five-year capital plan and currently looks forward to invest about $48.2 billion in its overall growth projects in the 2018-2022 time frame.
The Zacks analyst thinks this investment plan will drive earnings base growth in the company’s combined electric and gas businesses of approximately 6% over the next five years. It is also looking to invest heavily in cleaner power, natural gas infrastructure and the energy grid during the next 10 years.
In particular, Duke Energy will invest $11 billion to generate cleaner energy through renewables and natural gas as it moves to a low-carbon future. However, Duke Energy faces challenges from severe weather conditions and natural calamities, which may result in breaking down and damaging its infrastructure.
(You can read the full research report on Duke Energy here >>>).
Buy-ranked Stryker’s shares have gained +12% in the past year, outperforming the Zacks Medical Products industry, which has increased +1.4% over the same period. The Zacks analyst thinks that the company continues to gain from its Mako robotics platform, which has been the key driver of its core Orthopaedic segment.
In fact, the company witnessed solid growth in Mako robot installations in recent times. Surging domestic sales is another positive. Moreover, solid performance in emerging markets and Europe paints a bright picture. Solid expansion in operating margin is encouraging as well. Raised guidance for 2018 buoys optimism.
On the flip side, Stryker’s gross margin has been declining. Total debt on the balance sheet remains unchanged, adding to the company’s woes. The Trauma & Extremities business had moderate growth lately as it was affected by softness in the market and product supply issues. Stiff competition in the MedTech space is likely to mar Stryker’s prospects.
(You can read the full research report on Stryker here >>>).
Other noteworthy reports we are featuring today include Waste Management (WM - Free Report) , Kinder Morgan (KMI - Free Report) and PepsiCo (PEP - Free Report) .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>